Search Results
060 - Amarin Loses Vascepa Exclusivity in USA. Athersys Pivots to COVID-19.
Amarin CEO on Vascepa heart drug trial
AMARIN and VASCEPA - Rising from the ashes (again) ?
Amarin CEO John Thero on company’s FDA approval for key heart drug
Amarin CEO comments on its new medicine's mixed results in its drug trial
053 - Amarin Raises Guidance on Vascepa Label Expansion Approval. ASH Updates Impress!
New trick for old drug; Vascepa cost effective for CV reduction
Athersys, MultiStem and Covid-19
Will Amarin Case Put Judges in Charge of Drug Promotion?
Cell Therapy Treatments for COVID-19
Cell Therapies for COVID-19 - Athersys & Pluristem Therapeutics
WBB's Brozak Likes Biotime, Celldex, Athersys
